TK1 and benign neoplasm: Serum TK1 was subsequently investigated as a tumor marker using monoclonal or polyclonal antibodies against TK1, demonstrating significantly higher levels in preoperative breast cancer patients than in healthy volunteers or patients with benign tumors or following curative surgery for breast cancer [29].